International Journal of Clinical Reviews

Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis

Katerina M Antoniou, MD, PhD¹, and Demosthenes Bouros, MD, PhD, FCCP²

¹Department of Thoracic Medicine, Medical School, University of Crete, Heraklion; and ²Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece

Idiopathic pulmonary fibrosis (IPF) is the most lethal form of diffuse lung fibrosis, with approximately half of those affected dying within 2–3 years of diagnosis.

Metabolomics and IBD

Diane R Hildebrand, MB ChB, MRCS(Ed)¹, Natasha P Ross, MB ChB, MRCS(Ed)¹, and Angus JM Watson, MB ChB, FRCS(Ed), FRCS(Gen. Surg.)^1,2

¹Department of General Surgery, Raigmore Hospital, and²University of Stirling, Inverness, Scotland, UK

IBD is a chronic inflammatory condition with a high incidence in Northern Europe. Current biological markers are inadequate for detecting, phenotyping, and monitoring the disease. It is therefore imperative to find novel biomarkers that will not only help with diagnosis but that will also shed further light on the pathogenesis of IBD.

Three Cases of Mucormycosis from the Middle East: Different Risk Factors Leading to Different Outcomes

Tania A Baban, MD¹, Roy A Raad, MD², Dima Dandachi, MD¹, Souha S Kanj, MD¹, and Zeina A Kanafani, MD¹

¹Division of Infectious Diseases, Department of Internal Medicine; ²Department of Diagnostic Radiology, American University of Beirut Medical Center, Beirut, Lebanon

Mucormycosis is a devastating, rapidly progressive, life-threatening disease that necessitates urgent intervention, particularly in immunocompromised patients. So far, data on invasive mold infections from the Middle East and other developing countries are limited.

A New Specific Treatment for Hereditary Angioedema: Icatibant

Laurence Bouillet, MD, PhD

National Reference Centre for Angioedema, Grenoble University Hospital, Grenoble, France.

Hereditary angioedema (HAE) that is associated with C1 inhibitor deficiency is a rare disease, the prognosis of which is determined by upper respiratory tract involvement. In the absence of appropriate treatment, 25% of patients with this condition die of fatal asphyxia caused by laryngeal edema.

1 2 3 4

Find us on Facebook

READER SURVEY

» Click here to participate!

SUBMIT AN ARTICLE

» Click here

OTHER REMEDICA JOURNALS

» Click here to view!

Latest News

Latest Articles

Current Therapies and Approaches to the Treatment of Chronic Itch

Shields W Callahan, BA¹, and Peter A Lio, MD^1,2

¹Northwestern University Feinberg School of Medicine; and ²Dermatology and Aesthetics of Wicker Park, Chicago, IL, USA

Chronic itch is a distressing symptom that is often recalcitrant to standard anti-itch therapies. Distinct from acute itch in its duration and response to common treatments, chronic itch is a frustrating symptom for patients and their physicians alike.

» Read more

Categories: Dermatology

A New Specific Treatment for Hereditary Angioedema: Icatibant

Laurence Bouillet, MD, PhD

National Reference Centre for Angioedema, Grenoble University Hospital, Grenoble, France.

Hereditary angioedema (HAE) that is associated with C1 inhibitor deficiency is a rare disease, the prognosis of which is determined by upper respiratory tract involvement. In the absence of appropriate treatment, 25% of patients with this condition die of fatal asphyxia caused by laryngeal edema.

» Read more

Categories: Gastroenterology, Respiratory Medicine

Natural History of Non-Muscle-Invasive Bladder Cancer

Alon Z Weizer, MD, MS, Christopher Lee, MD, Khaled S Hafez, MD, and Jeffrey S Montgomery, MD, MHSA

University of Michigan, Ann Arbor, MI, USA

More than two-thirds of patients diagnosed with bladder cancer have tumor confined to the mucosa or lamina propria. These patients have non-muscle-invasive bladder cancer (NMIBC) amenable to interventions that preserve the bladder.

» Read more

Categories: Oncology, Urology

Metabolomics and IBD

Diane R Hildebrand, MB ChB, MRCS(Ed)¹, Natasha P Ross, MB ChB, MRCS(Ed)¹, and Angus JM Watson, MB ChB, FRCS(Ed), FRCS(Gen. Surg.)^1,2

¹Department of General Surgery, Raigmore Hospital, and²University of Stirling, Inverness, Scotland, UK

IBD is a chronic inflammatory condition with a high incidence in Northern Europe. Current biological markers are inadequate for detecting, phenotyping, and monitoring the disease. It is therefore imperative to find novel biomarkers that will not only help with diagnosis but that will also shed further light on the pathogenesis of IBD.

» Read more

Categories: Autoimmune Disease, Gastroenterology

Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis

Katerina M Antoniou, MD, PhD¹, and Demosthenes Bouros, MD, PhD, FCCP²

¹Department of Thoracic Medicine, Medical School, University of Crete, Heraklion; and ²Department of Pneumonology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece

Idiopathic pulmonary fibrosis (IPF) is the most lethal form of diffuse lung fibrosis, with approximately half of those affected dying within 2–3 years of diagnosis.

» Read more

Categories: Respiratory Medicine

Three Cases of Mucormycosis from the Middle East: Different Risk Factors Leading to Different Outcomes

Tania A Baban, MD¹, Roy A Raad, MD², Dima Dandachi, MD¹, Souha S Kanj, MD¹, and Zeina A Kanafani, MD¹

¹Division of Infectious Diseases, Department of Internal Medicine; ²Department of Diagnostic Radiology, American University of Beirut Medical Center, Beirut, Lebanon

Mucormycosis is a devastating, rapidly progressive, life-threatening disease that necessitates urgent intervention, particularly in immunocompromised patients. So far, data on invasive mold infections from the Middle East and other developing countries are limited.

» Read more

Categories: Infectious Diseases, Mycology

The Emerging Role of Cytokines in Breast Cancer: From Initiation to Survivorship

Sonali Jindal, MD, Virginia F Borges, MD, MMSc

University of Colorado Denver – Anschutz Medical Campus, Aurora, CO, USA

Breast cancer is the most common malignancy in US women and remains the leading cause of cancer death in women aged 15–54 years. The current understanding of breast cancer supports the concept of multifactorial causation, involving genomic alteration of epithelial cells coupled with an altered microenvironment supportive of tumor growth.

» Read more

Categories: Oncology

Vaccines Against Coccidioidomycosis: Past and Current Developments

Karl V Clemons, PhD, and David A Stevens, MD

Department of Medicine, Division of Infectious Diseases, Santa Clara Valley Medical Center and California Institute for Medical Research, San Jose, and Department of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA, USA

There are no commercially available vaccines for the prevention of coccidioidomycosis. This fungal infection, endemic to the Southwestern US and parts of Latin America, is estimated to cause ≥150 000 new infections each year, with exposure possible to approximately 20 million individuals in the US alone.

» Read more

Categories: Infectious Diseases, Mycology

Predicting Outcomes of Ulcerative Colitis: The Role of Biomarkers

Duk Hwan Kim, Won Ho Kim, and Jae Hee Cheon

Yonsei University College of Medicine, Seoul, Korea

Treatment planning for ulcerative colitis (UC) is based on disease severity and exact diagnosis, the latter of which is currently achieved through assessments of clinical presentation and typical endoscopic appearance coupled with histological confirmation [1–3].

» Read more

Categories: Autoimmune Disease, Gastroenterology

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.